Clinical Trials

Multiple clinical trials evaluate metabolic, neurological, hepatic, and gastrointestinal conditions, including amyotrophic lateral sclerosis, chronic hepatitis B, cystic fibrosis, and short bowel syndrome. Spanning Phase 1 through Phase 4 with recruitment statuses ranging from active and completed to not yet recruiting, these studies focus on immune function and metabolic intervention. Sponsoring entities include academic medical centers and health organizations such as Emory University, University Hospital Geneva, and the National Institute of Allergy and Infectious Diseases.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT05105958 Not yet recruiting
Amyotrophic Lateral Sclerosis
University Hospital Geneva|University of Lausanne Hospitals|University of Zurich|University of Bern|Cantonal Hospital of St. Gallen
2025-12-01 Phase 2
NCT05847179 Not yet recruiting
Werner Syndrome
PRG Science & Technology Co. Ltd.
2025-01-01 Phase 2
NCT06405555 Not yet recruiting
Heart Failure With Reduced Ejection Fraction|Hypotension|LV Dysfunction
Ottawa Heart Institute Research Corporation
2024-08-01 Phase 2|Phase 3
NCT05706116 Not yet recruiting
Whipworm|Trichuriasis|Controlled Human Infection
George Washington University|National Institute of Allergy and Infectious Diseases (NIAID)
2024-07-01 Phase 1
NCT04231565 RECRUITING
Hepatitis B Virus
Third Affiliated Hospital, Sun Yat-Sen University
2020-06-04
NCT05797714 ACTIVE_NOT_RECRUITING
HBV Infection; Chronic Hepatitis b
Ruijin Hospital
2022-06-08
NCT04022434 UNKNOWN
Fructose Intolerance
Augusta University
2014-01-07
NCT03341169 UNKNOWN
Aortic Valve Stenois
Yonsei University
2018-03-20
NCT02770417 COMPLETED
Chronic Obstructive Pulmonary Disease (COPD)
Hasselt University
2016-05
NCT01576003 COMPLETED
Bloodstream Infections; Short Bowel Syndrome; Development; Nutrition; Biological Markers
Children's Hospital Medical Center, Cincinnati
2012-04
NCT01944059 TERMINATED
Migraine Headaches
Vincent Martin, MD
2013-11 PHASE4
NCT01833611 UNKNOWN
Chronic Hepatitis
National Cheng-Kung University Hospital
2008-09 PHASE4
NCT00628381 UNKNOWN
Sepsis; Multiple Organ Failure
Maastricht University Medical Center
2011-01 PHASE3
NCT01478126 COMPLETED
Coronary Artery Disease
Meshalkin Research Institute of Pathology of Circulation
2012-01 PHASE3
NCT01288495 TERMINATED
Dietary Fructose Intolerance
Augusta University
2009-02
NCT01051999 COMPLETED
Cystic Fibrosis; Immune Function
Emory University
2010-02 PHASE2
NCT00575627 UNKNOWN
Chronic Hepatitis C
University of Turin, Italy
2007-09 PHASE4
NCT00586885 COMPLETED
Nonalcoholic Steatohepatitis
Keith D Lindor, M.D.
2004-02

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the L-Alanine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As a non-essential amino acid, L-alanine undergoes transamination by alanine aminotransferase to generate pyruvate, thereby fueling the tricarboxylic acid cycle and facilitating hepatic gluconeogenesis and muscular energy production. This fundamental metabolic pathway maintains cellular energy homeostasis and supports immune function, rendering L-alanine clinically relevant as a nutritional and metabolic support agent in conditions such as chronic hepatitis, cystic fibrosis, and metabolic dysregulation.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.